{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:04:58Z","timestamp":1791547498621,"version":"4.3.4"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-01009-8","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:13:36Z","timestamp":1786630416000},"page":"2301-2320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic Risk in Multiple Sclerosis: Susceptibility, Modifiers and Unresolved Questions"],"prefix":"10.1007","volume":"15","author":[{"given":"Jingni","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-4340","authenticated-orcid":false,"given":"Vilija G.","family":"Jokubaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"1009_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, et al. Multiple sclerosis. Lancet. 2024;403:183\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(23)01473-3.","journal-title":"Lancet"},{"key":"1009_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102247","volume":"44","author":"H Ahmad","year":"2020","unstructured":"Ahmad H, Campbell JA, van der Mei I, Taylor BV, Zhao T, Palmer AJ. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: results from updated and detailed data on types of costs. Mult Scler Relat Disord. 2020;44:102247. https:\/\/doi.org\/10.1016\/j.msard.2020.102247.","journal-title":"Mult Scler Relat Disord"},{"key":"1009_CR3","unstructured":"Campbell J, Henson G, van der Mei I, Taylor BV. Multiple sclerosis prevalence and health economic impact in Australia 2025. Online. 2025. https:\/\/www.msaustralia.org.au\/wp-content\/uploads\/ms-prevalence-and-health-economic-impact-in-australia-2025_web.pdf."},{"key":"1009_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841.","journal-title":"Mult Scler"},{"key":"1009_CR5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/1352458516671819","volume":"23","author":"K Ribbons","year":"2017","unstructured":"Ribbons K, Lea R, Tiedeman C, Mackenzie L, Lechner-Scott J. Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 50-year study. Mult Scler. 2017;23:1063\u201371. https:\/\/doi.org\/10.1177\/1352458516671819.","journal-title":"Mult Scler"},{"key":"1009_CR6","doi-asserted-by":"publisher","first-page":"e1954","DOI":"10.1212\/WNL.0000000000005612","volume":"90","author":"N Koch-Henriksen","year":"2018","unstructured":"Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology. 2018;90:e1954\u201363. https:\/\/doi.org\/10.1212\/WNL.0000000000005612.","journal-title":"Neurology"},{"key":"1009_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102637","volume":"47","author":"LH Hua","year":"2021","unstructured":"Hua LH, Hersh CM, Tian F, Mowry EM, Fitzgerald KC. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60. Mult Scler Relat Disord. 2021;47:102637. https:\/\/doi.org\/10.1016\/j.msard.2020.102637.","journal-title":"Mult Scler Relat Disord"},{"key":"1009_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Frenay C, Oh J, Arrambide G, Moccia M, Pia Amato M, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24:850\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4.","journal-title":"Lancet Neurol"},{"key":"1009_CR9","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1177\/1352458521994557","volume":"27","author":"B Bessing","year":"2021","unstructured":"Bessing B, Hussain MA, Claflin SB, Chen J, Blizzard L, van Dijk P, et al. Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis. Mult Scler. 2021;27:2093\u2013102. https:\/\/doi.org\/10.1177\/1352458521994557.","journal-title":"Mult Scler"},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00415-020-10195-w","volume":"268","author":"LMP Lo","year":"2021","unstructured":"Lo LMP, Taylor BV, Winzenberg T, Palmer AJ, Blizzard L, Ahmad H, et al. Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis. J Neurol. 2021;268:569\u201381. https:\/\/doi.org\/10.1007\/s00415-020-10195-w.","journal-title":"J Neurol"},{"key":"1009_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/acn3.52267","volume":"12","author":"H Tremlett","year":"2025","unstructured":"Tremlett H, Zhu F, Everett K, Asaf A, Manouchehrinia A, Li P, et al. Healthcare use is elevated two decades before a first demyelinating event and differs by age and sex. Ann Clin Transl Neurol. 2025;12:415\u201332. https:\/\/doi.org\/10.1002\/acn3.52267.","journal-title":"Ann Clin Transl Neurol"},{"key":"1009_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77:1132\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568.","journal-title":"JAMA Neurol"},{"key":"1009_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J Muller","year":"2023","unstructured":"Muller J, Cagol A, Lorscheider J, Tsagkas C, Benkert P, Yaldizli O, et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol. 2023;80:1232\u201345. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331.","journal-title":"JAMA Neurol"},{"key":"1009_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000341902","volume":"40","author":"C O\u2019Gorman","year":"2013","unstructured":"O\u2019Gorman C, Lin R, Stankovich J, Broadley SA. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology. 2013;40:1\u201312. https:\/\/doi.org\/10.1159\/000341902.","journal-title":"Neuroepidemiology"},{"key":"1009_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2025.12.046","volume":"189","author":"J Wang","year":"2026","unstructured":"Wang J, Qiu Y, Marti Z, Li F, Wacker M, Oldrati P, et al. EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. Cell. 2026;189:569\u201384 e514. https:\/\/doi.org\/10.1016\/j.cell.2025.12.046.","journal-title":"Cell"},{"key":"1009_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fneur.2019.00134","volume":"10","author":"K Hocevar","year":"2019","unstructured":"Hocevar K, Ristic S, Peterlin B. Pharmacogenomics of multiple sclerosis: a systematic review. Front Neurol. 2019;10:134. https:\/\/doi.org\/10.3389\/fneur.2019.00134.","journal-title":"Front Neurol"},{"key":"1009_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.msard.2017.12.015","volume":"20","author":"MH Harirchian","year":"2018","unstructured":"Harirchian MH, Fatehi F, Sarraf P, Honarvar NM, Bitarafan S. Worldwide prevalence of familial multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2018;20:43\u20137. https:\/\/doi.org\/10.1016\/j.msard.2017.12.015.","journal-title":"Mult Scler Relat Disord"},{"key":"1009_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1177\/13524585231185258","volume":"29","author":"GS Boles","year":"2023","unstructured":"Boles GS, Hillert J, Ramanujam R, Westerlind H, Olsson T, Kockum I, et al. The familial risk and heritability of multiple sclerosis and its onset phenotypes: a case-control study. Mult Scler. 2023;29:1209\u201315. https:\/\/doi.org\/10.1177\/13524585231185258.","journal-title":"Mult Scler"},{"key":"1009_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/1352458509104592","volume":"15","author":"CH Hawkes","year":"2009","unstructured":"Hawkes CH, Macgregor AJ. Twin studies and the heritability of MS: a conclusion. Mult Scler. 2009;15:661\u20137. https:\/\/doi.org\/10.1177\/1352458509104592.","journal-title":"Mult Scler"},{"key":"1009_CR20","doi-asserted-by":"publisher","first-page":"12877","DOI":"10.1073\/pnas.1932604100","volume":"100","author":"CJ Willer","year":"2003","unstructured":"Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC, Canadian Collaborative Study, G. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA. 2003;100:12877\u201382. https:\/\/doi.org\/10.1073\/pnas.1932604100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1009_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41586-022-04419-4","volume":"603","author":"F Ingelfinger","year":"2022","unstructured":"Ingelfinger F, Gerdes LA, Kavaka V, Krishnarajah S, Friebel E, Galli E, et al. Twin study reveals non-heritable immune perturbations in multiple sclerosis. Nature. 2022;603:152\u20138. https:\/\/doi.org\/10.1038\/s41586-022-04419-4.","journal-title":"Nature"},{"key":"1009_CR22","doi-asserted-by":"publisher","first-page":"21546","DOI":"10.1073\/pnas.2003339117","volume":"117","author":"LA Gerdes","year":"2020","unstructured":"Gerdes LA, Janoschka C, Eveslage M, Mannig B, Wirth T, Schulte-Mecklenbeck A, et al. Immune signatures of prodromal multiple sclerosis in monozygotic twins. Proc Natl Acad Sci USA. 2020;117:21546\u201356. https:\/\/doi.org\/10.1073\/pnas.2003339117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1009_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7188","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019. https:\/\/doi.org\/10.1126\/science.aav7188.","journal-title":"Science"},{"key":"1009_CR24","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.cell.2018.09.049","volume":"175","author":"International Multiple Sclerosis Genetics Consortium","year":"2018","unstructured":"International Multiple Sclerosis Genetics Consortium. Low-frequency and rare-coding variation contributes to multiple sclerosis risk. Cell. 2018;175:1679\u201387. https:\/\/doi.org\/10.1016\/j.cell.2018.09.049.","journal-title":"Cell."},{"key":"1009_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41588-021-00997-7","volume":"54","author":"P Wainschtein","year":"2022","unstructured":"Wainschtein P, Jain D, Zheng Z, TOPMED Anthropometry Working Group, NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Cupples LA, Shadyab AH, McKnight B, Shoemaker BM, Mitchell BD, et al. Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. Nat Genet. 2022;54:263\u201373. https:\/\/doi.org\/10.1038\/s41588-021-00997-7.","journal-title":"Nat Genet"},{"key":"1009_CR26","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/jnnp-2020-325676","volume":"92","author":"AK Hedstrom","year":"2021","unstructured":"Hedstrom AK, Hillert J, Brenner N, Butt J, Waterboer T, Strid P, et al. DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies. J Neurol Neurosurg Psychiatry. 2021;92:717\u201322. https:\/\/doi.org\/10.1136\/jnnp-2020-325676.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1009_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/13524585221139767","volume":"29","author":"VG Jokubaitis","year":"2023","unstructured":"Jokubaitis VG. A role for HLA in mediating long-term multiple sclerosis outcomes? Mult Scler. 2023;29:314\u20136. https:\/\/doi.org\/10.1177\/13524585221139767.","journal-title":"Mult Scler"},{"key":"1009_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa073493","volume":"357","author":"DA Hafler","year":"2007","unstructured":"International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851\u201362. https:\/\/doi.org\/10.1056\/NEJMoa073493.","journal-title":"N Engl J Med"},{"key":"1009_CR29","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1177\/1352458517733551","volume":"24","author":"MA Gianfrancesco","year":"2018","unstructured":"Gianfrancesco MA, Stridh P, Shao X, Rhead B, Graves JS, Chitnis T, et al. Genetic risk factors for pediatric-onset multiple sclerosis. Mult Scler. 2018;24:1825\u201334. https:\/\/doi.org\/10.1177\/1352458517733551.","journal-title":"Mult Scler"},{"key":"1009_CR30","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s0140-6736(72)90962-2","volume":"1","author":"C Jersild","year":"1972","unstructured":"Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet. 1972;1:1240\u20131. https:\/\/doi.org\/10.1016\/s0140-6736(72)90962-2.","journal-title":"Lancet"},{"key":"1009_CR31","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1086\/323480","volume":"69","author":"A Ligers","year":"2001","unstructured":"Ligers A, Dyment DA, Willer CJ, Sadovnick AD, Ebers G, Risch N, et al. Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis. Am J Hum Genet. 2001;69:900\u20133. https:\/\/doi.org\/10.1086\/323480.","journal-title":"Am J Hum Genet"},{"key":"1009_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1086\/444547","volume":"77","author":"S Sawcer","year":"2005","unstructured":"Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet. 2005;77:454\u201367. https:\/\/doi.org\/10.1086\/444547.","journal-title":"Am J Hum Genet"},{"key":"1009_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/archneur.56.5.555","volume":"56","author":"OJ Kwon","year":"1999","unstructured":"Kwon OJ, Karni A, Israel S, Brautbar C, Amar A, Meiner Z, et al. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol. 1999;56:555\u201360. https:\/\/doi.org\/10.1001\/archneur.56.5.555.","journal-title":"Arch Neurol"},{"key":"1009_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/hmg\/ddn388","volume":"18","author":"SE Baranzini","year":"2009","unstructured":"Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009;18:767\u201378. https:\/\/doi.org\/10.1093\/hmg\/ddn388.","journal-title":"Hum Mol Genet"},{"key":"1009_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ng.401","volume":"41","author":"PL De Jager","year":"2009","unstructured":"De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41:776\u201382. https:\/\/doi.org\/10.1038\/ng.401.","journal-title":"Nat Genet"},{"key":"1009_CR36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/ng.396","volume":"41","author":"The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)","year":"2009","unstructured":"The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824\u20138. https:\/\/doi.org\/10.1038\/ng.396.","journal-title":"Nat Genet"},{"key":"1009_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"S Sawcer","year":"2011","unstructured":"International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214\u20139. https:\/\/doi.org\/10.1038\/nature10251.","journal-title":"Nature"},{"key":"1009_CR38","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/ana.22609","volume":"70","author":"NA Patsopoulos","year":"2011","unstructured":"Patsopoulos NA, Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFN\u03b2-1b and a CCR1-Antagonist, ANZGene Consortium, Gene MSA, International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011;70:897\u2013912. https:\/\/doi.org\/10.1002\/ana.22609.","journal-title":"Ann Neurol"},{"key":"1009_CR39","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ng.2770","volume":"45","author":"AH Beecham","year":"2013","unstructured":"International Multiple Sclerosis Genetics Consortium, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353\u201360. https:\/\/doi.org\/10.1038\/ng.2770.","journal-title":"Nat Genet"},{"key":"1009_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ajhg.2007.09.001","volume":"82","author":"S Leslie","year":"2008","unstructured":"Leslie S, Donnelly P, McVean G. A statistical method for predicting classical HLA alleles from SNP data. Am J Hum Genet. 2008;82:48\u201356. https:\/\/doi.org\/10.1016\/j.ajhg.2007.09.001.","journal-title":"Am J Hum Genet"},{"key":"1009_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002877","volume":"9","author":"A Dilthey","year":"2013","unstructured":"Dilthey A, Leslie S, Moutsianas L, Shen J, Cox C, Nelson MR, et al. Multi-population classical HLA type imputation. PLoS Comput Biol. 2013;9:e1002877. https:\/\/doi.org\/10.1371\/journal.pcbi.1002877.","journal-title":"PLoS Comput Biol"},{"key":"1009_CR42","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/ng.3395","volume":"47","author":"L Moutsianas","year":"2015","unstructured":"Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 2015;47:1107\u201313. https:\/\/doi.org\/10.1038\/ng.3395.","journal-title":"Nat Genet"},{"key":"1009_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003926","volume":"9","author":"NA Patsopoulos","year":"2013","unstructured":"Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 2013;9:e1003926. https:\/\/doi.org\/10.1371\/journal.pgen.1003926.","journal-title":"PLoS Genet"},{"key":"1009_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279132","volume":"17","author":"AH Beecham","year":"2022","unstructured":"Beecham AH, Amezcua L, Chinea A, Manrique CP, Gomez L, Martinez A, et al. Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population. PLoS ONE. 2022;17:e0279132. https:\/\/doi.org\/10.1371\/journal.pone.0279132.","journal-title":"PLoS ONE"},{"key":"1009_CR45","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41588-021-00935-7","volume":"53","author":"Y Luo","year":"2021","unstructured":"Luo Y, Kanai M, Choi W, Li X, Sakaue S, Yamamoto K, et al. A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nat Genet. 2021;53:1504\u201316. https:\/\/doi.org\/10.1038\/s41588-021-00935-7.","journal-title":"Nat Genet"},{"key":"1009_CR46","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1093\/bioinformatics\/btz235","volume":"35","author":"AT Dilthey","year":"2019","unstructured":"Dilthey AT, Mentzer AJ, Carapito R, Cutland C, Cereb N, Madhi SA, et al. HLA*LA-HLA typing from linearly projected graph alignments. Bioinformatics. 2019;35:4394\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btz235.","journal-title":"Bioinformatics"},{"key":"1009_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/tan.13619","volume":"94","author":"AG Smith","year":"2019","unstructured":"Smith AG, Pereira S, Jaramillo A, Stoll ST, Khan FM, Berka N, et al. Comparison of sequence-specific oligonucleotide probe vs next generation sequencing for HLA-A, B, C, DRB1, DRB3\/B4\/B5, DQA1, DQB1, DPA1, and DPB1 typing: toward single-pass high-resolution HLA typing in support of solid organ and hematopoietic cell transplant programs. HLA. 2019;94:296\u2013306. https:\/\/doi.org\/10.1111\/tan.13619.","journal-title":"HLA"},{"key":"1009_CR48","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41596-023-00853-4","volume":"18","author":"S Sakaue","year":"2023","unstructured":"Sakaue S, Gurajala S, Curtis M, Luo Y, Choi W, Ishigaki K, et al. Tutorial: a statistical genetics guide to identifying HLA alleles driving complex disease. Nat Protoc. 2023;18:2625\u201341. https:\/\/doi.org\/10.1038\/s41596-023-00853-4.","journal-title":"Nat Protoc"},{"key":"1009_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09773-y","volume":"10","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium. A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nat Commun. 2019;10:2236. https:\/\/doi.org\/10.1038\/s41467-019-09773-y.","journal-title":"Nat Commun"},{"key":"1009_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","volume":"518","author":"KK Farh","year":"2015","unstructured":"Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518:337\u201343. https:\/\/doi.org\/10.1038\/nature13835.","journal-title":"Nature"},{"key":"1009_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02694-y","volume":"23","author":"MH Guo","year":"2022","unstructured":"Guo MH, Sama P, LaBarre BA, Lokhande H, Balibalos J, Chu C, et al. Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets. Genome Biol. 2022;23:127. https:\/\/doi.org\/10.1186\/s13059-022-02694-y.","journal-title":"Genome Biol"},{"key":"1009_CR52","doi-asserted-by":"publisher","unstructured":"De Jager P, Zeng L, Khan A, Lama T, International Multiple Sclerosis Genetics Consortium, Chitnis T, Weiner H, Wang G, Fujita M, Zipp F, Taga M, Kiryluk K. GWAS highlights the neuronal contribution to multiple sclerosis susceptibility. 2025. ResSq Preprint 6:rs.3.rs-5644532. https:\/\/doi.org\/10.21203\/rs.3.rs-5644532\/v1.","DOI":"10.21203\/rs.3.rs-5644532\/v1"},{"key":"1009_CR53","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/ng.396","volume":"41","author":"Australia, and New Zealand Multiple Sclerosis Genetics Consortium","year":"2009","unstructured":"Australia, and New Zealand Multiple Sclerosis Genetics Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824\u20138. https:\/\/doi.org\/10.1038\/ng.396.","journal-title":"Nat Genet"},{"key":"1009_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000053","volume":"1","author":"AK Kemppinen","year":"2011","unstructured":"Kemppinen AK, Kaprio J, Palotie A, Saarela J. Systematic review of genome-wide expression studies in multiple sclerosis. BMJ Open. 2011;1:e000053. https:\/\/doi.org\/10.1136\/bmjopen-2011-000053.","journal-title":"BMJ Open"},{"key":"1009_CR55","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/gene.2010.28","volume":"11","author":"International Multiple Sclerosis Genetics Consortium","year":"2010","unstructured":"International Multiple Sclerosis Genetics Consortium. IL12A, MPHOSPH9\/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes Immun. 2010;11:397\u2013405. https:\/\/doi.org\/10.1038\/gene.2010.28.","journal-title":"Genes Immun"},{"key":"1009_CR56","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/gene.2008.22","volume":"9","author":"IA Hoppenbrouwers","year":"2008","unstructured":"Hoppenbrouwers IA, Aulchenko YS, Ebers GC, Ramagopalan SV, Oostra BA, van Duijn CM, et al. EVI5 is a risk gene for multiple sclerosis. Genes Immun. 2008;9:334\u20137. https:\/\/doi.org\/10.1038\/gene.2008.22.","journal-title":"Genes Immun"},{"key":"1009_CR57","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000650","author":"MM Gresle","year":"2020","unstructured":"Gresle MM, Jordan MA, Stankovich J, Spelman T, Johnson LJ, Laverick L, et al. Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. Life Sci Alliance. 2020. https:\/\/doi.org\/10.26508\/lsa.202000650.","journal-title":"Life Sci Alliance"},{"key":"1009_CR58","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/13524585221150736","volume":"29","author":"MK Horton","year":"2023","unstructured":"Horton MK, Shim JE, Wallace A, Graves JS, Aaen G, Greenberg B, et al. Rare and low-frequency coding genetic variants contribute to pediatric-onset multiple sclerosis. Mult Scler. 2023;29:505\u201311. https:\/\/doi.org\/10.1177\/13524585221150736.","journal-title":"Mult Scler"},{"key":"1009_CR59","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/brain\/awaf038","volume":"148","author":"H Liu","year":"2025","unstructured":"Liu H, Marsh TW, Shi X, Renton AE, Bowling KM, Ziegemeier E, et al. The landscape of autosomal-dominant Alzheimer\u2019s disease: global distribution and age of onset. Brain. 2025;148:2429\u201340. https:\/\/doi.org\/10.1093\/brain\/awaf038.","journal-title":"Brain"},{"key":"1009_CR60","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1093\/brain\/awae188","volume":"147","author":"A Westenberger","year":"2024","unstructured":"Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt EJ, Laabs BH, et al. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson\u2019s disease study. Brain. 2024;147:2652\u201367. https:\/\/doi.org\/10.1093\/brain\/awae188.","journal-title":"Brain"},{"key":"1009_CR61","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41380-018-0073-x","volume":"24","author":"DC Glahn","year":"2019","unstructured":"Glahn DC, Nimgaonkar VL, Raventos H, Contreras J, McIntosh AM, Thomson PA, et al. Rediscovering the value of families for psychiatric genetics research. Mol Psychiatry. 2019;24:523\u201335. https:\/\/doi.org\/10.1038\/s41380-018-0073-x.","journal-title":"Mol Psychiatry"},{"key":"1009_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/9268911","volume":"2024","author":"M Chen","year":"2024","unstructured":"Chen M, Motyer A, Taylor BV, McComish BJ, Burdon KP, Charlesworth JC, et al. Multiple sclerosis polygenic risk is not enriched in three multicase families in comparison to population-based cases. Hum Mutat. 2024;2024:1\u20138. https:\/\/doi.org\/10.1155\/2024\/9268911.","journal-title":"Hum Mutat"},{"key":"1009_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577760","volume":"362","author":"E Mascia","year":"2022","unstructured":"Mascia E, Clarelli F, Zauli A, Guaschino C, Sorosina M, Barizzone N, et al. Burden of rare coding variants in an Italian cohort of familial multiple sclerosis. J Neuroimmunol. 2022;362:577760. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577760.","journal-title":"J Neuroimmunol"},{"key":"1009_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94691-x","volume":"15","author":"F Buyukgol","year":"2025","unstructured":"Buyukgol F, Gurdamar B, Aluclu MU, Beckmann Y, Bilguvar K, Boz C, et al. Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families. Sci Rep. 2025;15:11682. https:\/\/doi.org\/10.1038\/s41598-025-94691-x.","journal-title":"Sci Rep"},{"key":"1009_CR65","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.neuron.2016.04.039","volume":"90","author":"Z Wang","year":"2016","unstructured":"Wang Z, Sadovnick AD, Traboulsee AL, Ross JP, Bernales CQ, Encarnacion M, et al. Nuclear receptor NR1H3 in familial multiple sclerosis. Neuron. 2016;90:948\u201354. https:\/\/doi.org\/10.1016\/j.neuron.2016.04.039.","journal-title":"Neuron"},{"key":"1009_CR66","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.neuron.2016.09.054","volume":"92","author":"EV Minikel","year":"2016","unstructured":"Minikel EV, MacArthur DG. Publicly available data provide evidence against NR1H3 R415Q causing multiple sclerosis. Neuron. 2016;92:336\u20138. https:\/\/doi.org\/10.1016\/j.neuron.2016.09.054.","journal-title":"Neuron"},{"key":"1009_CR67","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/humu.23218","volume":"38","author":"AD Sadovnick","year":"2017","unstructured":"Sadovnick AD, Gu BJ, Traboulsee AL, Bernales CQ, Encarnacion M, Yee IM, et al. Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis. Hum Mutat. 2017;38:736\u201344. https:\/\/doi.org\/10.1002\/humu.23218.","journal-title":"Hum Mutat"},{"key":"1009_CR68","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ana.22678","volume":"70","author":"SV Ramagopalan","year":"2011","unstructured":"Ramagopalan SV, Dyment DA, Cader MZ, Morrison KM, Disanto G, Morahan JM, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol. 2011;70:881\u20136. https:\/\/doi.org\/10.1002\/ana.22678.","journal-title":"Ann Neurol"},{"key":"1009_CR69","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1212\/WNL.0b013e3182616fc4","volume":"79","author":"DA Dyment","year":"2012","unstructured":"Dyment DA, Cader MZ, Chao MJ, Lincoln MR, Morrison KM, Disanto G, et al. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology. 2012;79:406\u201311. https:\/\/doi.org\/10.1212\/WNL.0b013e3182616fc4.","journal-title":"Neurology"},{"key":"1009_CR70","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1038\/s41598-017-03536-9","volume":"7","author":"A Maver","year":"2017","unstructured":"Maver A, Lavtar P, Ristic S, Stopinsek S, Simcic S, Hocevar K, et al. Identification of rare genetic variation of NLRP1 gene in familial multiple sclerosis. Sci Rep. 2017;7:3715. https:\/\/doi.org\/10.1038\/s41598-017-03536-9.","journal-title":"Sci Rep"},{"key":"1009_CR71","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1007\/s13369-020-05242-7","volume":"46","author":"AM Alkhateeb","year":"2021","unstructured":"Alkhateeb AM, Salman DS, Al-Hayk KA. Exome sequencing analysis of familial cases of multiple sclerosis and a monozygotic discordant twin. Arab J Sci Eng. 2021;46:5421\u20137. https:\/\/doi.org\/10.1007\/s13369-020-05242-7.","journal-title":"Arab J Sci Eng"},{"key":"1009_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000451","volume":"17","author":"M Gharagozloo","year":"2019","unstructured":"Gharagozloo M, Mahmoud S, Simard C, Yamamoto K, Bobbala D, Ilangumaran S, et al. NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity. PLoS Biol. 2019;17:e3000451. https:\/\/doi.org\/10.1371\/journal.pbio.3000451.","journal-title":"PLoS Biol"},{"key":"1009_CR73","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41397-019-0100-6","volume":"19","author":"M Encarnacion","year":"2019","unstructured":"Encarnacion M, Bernales CQ, Traboulsee AL, Sadovnick AD, Vilarino-Guell C. Analysis of galanin receptor GALR2 in multiple sclerosis. Pharmacogenomics J. 2019;19:499\u2013500. https:\/\/doi.org\/10.1038\/s41397-019-0100-6.","journal-title":"Pharmacogenomics J"},{"key":"1009_CR74","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00251-020-01170-w","volume":"72","author":"LF Popplewell","year":"2020","unstructured":"Popplewell LF, Encarnacion M, Bernales CQ, Sadovnick AD, Traboulsee AL, Quandt JA, et al. Genetic analysis of nucleotide-binding leucine-rich repeat (NLR) receptors in multiple sclerosis. Immunogenetics. 2020;72:381\u20135. https:\/\/doi.org\/10.1007\/s00251-020-01170-w.","journal-title":"Immunogenetics"},{"key":"1009_CR75","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11910-015-0576-7","volume":"15","author":"M Toledano","year":"2015","unstructured":"Toledano M, Weinshenker BG, Solomon AJ. A clinical approach to the differential diagnosis of multiple sclerosis. Curr Neurol Neurosci Rep. 2015;15:57. https:\/\/doi.org\/10.1007\/s11910-015-0576-7.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1009_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-22027","author":"WY Yau","year":"2017","unstructured":"Yau WY, Fabis-Pedrini MJ, Kermode AG. Fabry heterozygote mimicking multiple sclerosis. BMJ Case Rep. 2017;2017. https:\/\/doi.org\/10.1136\/bcr-2017-220274.","journal-title":"BMJ Case Rep"},{"key":"1009_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00860","volume":"11","author":"A Khan","year":"2020","unstructured":"Khan A, Abedi V, Li J, Malik MT, Esch M, Zand R. CADASIL vs. multiple sclerosis: is it misdiagnosis or concomitant? A case series. Front Neurol. 2020;11:860. https:\/\/doi.org\/10.3389\/fneur.2020.00860.","journal-title":"Front Neurol"},{"key":"1009_CR78","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1212\/01.wnl.0000304045.99153.8f","volume":"70","author":"BM Keegan","year":"2008","unstructured":"Keegan BM, Giannini C, Parisi JE, Lucchinetti CF, Boeve BF, Josephs KA. Sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MS. Neurology. 2008;70:1128\u201333. https:\/\/doi.org\/10.1212\/01.wnl.0000304045.99153.8f.","journal-title":"Neurology"},{"key":"1009_CR79","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jns.2017.01.069","volume":"375","author":"A Rubegni","year":"2017","unstructured":"Rubegni A, Battisti C, Tessa A, Cerase A, Doccini S, Malandrini A, et al. SPG2 mimicking multiple sclerosis in a family identified using next generation sequencing. J Neurol Sci. 2017;375:198\u2013202. https:\/\/doi.org\/10.1016\/j.jns.2017.01.069.","journal-title":"J Neurol Sci"},{"key":"1009_CR80","doi-asserted-by":"publisher","DOI":"10.1177\/20552173241263491","volume":"10","author":"JM Mandler","year":"2024","unstructured":"Mandler JM, Hartl J, Cordts I, Sturm M, Hedderich DM, Bafligil C, et al. Uncovering genetic mimics in multiple sclerosis: a single-center clinical exome sequencing study. Mult Scler J Exp Transl Clin. 2024;10:20552173241263491. https:\/\/doi.org\/10.1177\/20552173241263491.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"1009_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01582-x","volume":"17","author":"NB Blackburn","year":"2025","unstructured":"Blackburn NB, McComish BJ, Motyer A, Slimmer JC, Leslie SJ, Broadley SA, et al. Rare variation in neurological disease genes and its role in multiple sclerosis mimicry and phenotype. Genome Med. 2025;17:149. https:\/\/doi.org\/10.1186\/s13073-025-01582-x.","journal-title":"Genome Med"},{"key":"1009_CR82","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2405459","volume":"393","author":"F Rahimov","year":"2025","unstructured":"Rahimov F, Jacobs BM, Lee JS, Mahi NA, Blumenfeld A, Alsheikh AJ, et al. Common diseases in clinical cohorts\u2014not always what they seem. N Engl J Med. 2025;393:1589\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2405459.","journal-title":"N Engl J Med"},{"key":"1009_CR83","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1352458510389101","volume":"17","author":"A Van der Walt","year":"2011","unstructured":"Van der Walt A, Stankovich J, Bahlo M, Taylor BV, Van der Mei IA, Foote SJ, et al. Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. Mult Scler. 2011;17:344\u201352. https:\/\/doi.org\/10.1177\/1352458510389101.","journal-title":"Mult Scler"},{"key":"1009_CR84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/1531-8249(200008)48:2<211::AID-ANA11>3.0.CO;2-R","volume":"48","author":"T Masterman","year":"2000","unstructured":"Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000;48:211\u20139.","journal-title":"Ann Neurol"},{"key":"1009_CR85","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/brain\/awac449","volume":"146","author":"VG Jokubaitis","year":"2023","unstructured":"Jokubaitis VG, Campagna MP, Ibrahim O, Stankovich J, Kleinova P, Matesanz F, et al. Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity. Brain. 2023;146:2316\u201331. https:\/\/doi.org\/10.1093\/brain\/awac449.","journal-title":"Brain"},{"key":"1009_CR86","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1086\/367781","volume":"72","author":"LF Barcellos","year":"2003","unstructured":"Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003;72:710\u20136. https:\/\/doi.org\/10.1086\/367781.","journal-title":"Am J Hum Genet"},{"key":"1009_CR87","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","volume":"619","author":"International Multiple Sclerosis Genetics Consortium","year":"2023","unstructured":"International Multiple Sclerosis Genetics Consortium, MultipleMS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature. 2023;619:323\u201331. https:\/\/doi.org\/10.1038\/s41586-023-06250-x.","journal-title":"Nature"},{"key":"1009_CR88","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000087","volume":"2","author":"MF George","year":"2016","unstructured":"George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, et al. Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurol Genet. 2016;2:e87. https:\/\/doi.org\/10.1212\/NXG.0000000000000087.","journal-title":"Neurol Genet"},{"key":"1009_CR89","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/gene.2011.34","volume":"12","author":"International Multiple Sclerosis Genetics Consortium","year":"2011","unstructured":"International Multiple Sclerosis Genetics Consortium. Genome-wide association study of severity in multiple sclerosis. Genes Immun. 2011;12:615\u201325. https:\/\/doi.org\/10.1038\/gene.2011.34.","journal-title":"Genes Immun"},{"key":"1009_CR90","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-023-06618-z","volume":"625","author":"W Barrie","year":"2024","unstructured":"Barrie W, Yang Y, Irving-Pease EK, Attfield KE, Scorrano G, Jensen LT, et al. Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations. Nature. 2024;625:321\u20138. https:\/\/doi.org\/10.1038\/s41586-023-06618-z.","journal-title":"Nature"},{"key":"1009_CR91","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296\u2013301. https:\/\/doi.org\/10.1126\/science.abj8222.","journal-title":"Science"},{"key":"1009_CR92","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awag111","author":"BM Jacobs","year":"2026","unstructured":"Jacobs BM, Vandebergh M, Maltby VE, Dobson R, Kreft KL. Interplay between genetic and environmental risk factors in multiple sclerosis: what have we learned? Brain. 2026. https:\/\/doi.org\/10.1093\/brain\/awag111.","journal-title":"Brain"},{"key":"1009_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2025-001313","volume":"7","author":"K Ward","year":"2025","unstructured":"Ward K, Li V, Ramanathan S, Hall LA, Buzzard K, Young K, et al. Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of spironolactone and famciclovir in the treatment of progressive multiple sclerosis to prevent disability progression: the STOP-MS trial. BMJ Neurol Open. 2025;7:e001313. https:\/\/doi.org\/10.1136\/bmjno-2025-001313.","journal-title":"BMJ Neurol Open"},{"key":"1009_CR94","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","volume":"296","author":"KL Munger","year":"2006","unstructured":"Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832\u20138. https:\/\/doi.org\/10.1001\/jama.296.23.2832.","journal-title":"JAMA"},{"key":"1009_CR95","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/WNL.0000000000003849","volume":"88","author":"MA Gianfrancesco","year":"2017","unstructured":"Gianfrancesco MA, Stridh P, Rhead B, Shao X, Xu E, Graves JS, et al. Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology. 2017;88:1623\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000003849.","journal-title":"Neurology"},{"key":"1009_CR96","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000662","author":"BM Jacobs","year":"2020","unstructured":"Jacobs BM, Noyce AJ, Giovannoni G, Dobson R. BMI and low vitamin D are causal factors for multiple sclerosis: a Mendelian randomization study. Neurol Neuroimmunol Neuroinflamm. 2020. https:\/\/doi.org\/10.1212\/NXI.0000000000000662.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1009_CR97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2302259121","volume":"121","author":"C Adams","year":"2024","unstructured":"Adams C, Manouchehrinia A, Quach HL, Quach DL, Olsson T, Kockum I, et al. Evidence supports a causal association between allele-specific vitamin D receptor binding and multiple sclerosis among Europeans. Proc Natl Acad Sci USA. 2024;121:e2302259121. https:\/\/doi.org\/10.1073\/pnas.2302259121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1009_CR98","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/jnnp-2018-320189","volume":"90","author":"S Simpson Jr.","year":"2019","unstructured":"Simpson S Jr., Wang W, Otahal P, Blizzard L, van der Mei IAF, Taylor BV. Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis. J Neurol Neurosurg Psychiatry. 2019;90:1193\u2013200. https:\/\/doi.org\/10.1136\/jnnp-2018-320189.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1009_CR99","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/brain\/awad409","volume":"147","author":"H Butzkueven","year":"2024","unstructured":"Butzkueven H, Ponsonby AL, Stein MS, Lucas RM, Mason D, Broadley S, et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain. 2024;147:1206\u201315. https:\/\/doi.org\/10.1093\/brain\/awad409.","journal-title":"Brain"},{"key":"1009_CR100","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jama.2025.1604","volume":"333","author":"E Thouvenot","year":"2025","unstructured":"Thouvenot E, Laplaud D, Lebrun-Frenay C, Derache N, Le Page E, Maillart E, et al. High-dose vitamin D in clinically isolated syndrome typical of multiple sclerosis: the D-Lay MS randomized clinical trial. JAMA. 2025;333:1413\u201322. https:\/\/doi.org\/10.1001\/jama.2025.1604.","journal-title":"JAMA"},{"key":"1009_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000369","volume":"5","author":"SV Ramagopalan","year":"2009","unstructured":"Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009;5:e1000369. https:\/\/doi.org\/10.1371\/journal.pgen.1000369.","journal-title":"PLoS Genet"},{"key":"1009_CR102","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1093\/hmg\/ddx092","volume":"26","author":"G Gallone","year":"2017","unstructured":"Gallone G, Haerty W, Disanto G, Ramagopalan SV, Ponting CP, Berlanga-Taylor AJ. Identification of genetic variants affecting vitamin D receptor binding and associations with autoimmune disease. Hum Mol Genet. 2017;26:2164\u201376. https:\/\/doi.org\/10.1093\/hmg\/ddx092.","journal-title":"Hum Mol Genet"},{"key":"1009_CR103","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jmedgenet-2012-101085","volume":"50","author":"A Alcina","year":"2013","unstructured":"Alcina A, Fedetz M, Fernandez O, Saiz A, Izquierdo G, Lucas M, et al. Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. J Med Genet. 2013;50:25\u201333. https:\/\/doi.org\/10.1136\/jmedgenet-2012-101085.","journal-title":"J Med Genet"},{"key":"1009_CR104","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1111\/bph.15201","volume":"177","author":"WZ Yeh","year":"2020","unstructured":"Yeh WZ, Gresle M, Jokubaitis V, Stankovich J, van der Walt A, Butzkueven H. Immunoregulatory effects and therapeutic potential of vitamin D in multiple sclerosis. Br J Pharmacol. 2020;177:4113\u201333. https:\/\/doi.org\/10.1111\/bph.15201.","journal-title":"Br J Pharmacol"},{"key":"1009_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110183","volume":"262","author":"WZ Yeh","year":"2024","unstructured":"Yeh WZ, Gresle M, Lea R, Taylor B, Lucas RM, Ponsonby AL, et al. The immune cell transcriptome is modulated by vitamin D(3) supplementation in people with a first demyelinating event participating in a randomized placebo-controlled trial. Clin Immunol. 2024;262:110183. https:\/\/doi.org\/10.1016\/j.clim.2024.110183.","journal-title":"Clin Immunol"},{"key":"1009_CR106","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41598-024-51779-0","volume":"14","author":"WZ Yeh","year":"2024","unstructured":"Yeh WZ, Lea R, Stankovich J, Sampangi S, Laverick L, Van der Walt A, et al. Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis. Sci Rep. 2024;14:1436. https:\/\/doi.org\/10.1038\/s41598-024-51779-0.","journal-title":"Sci Rep"},{"key":"1009_CR107","doi-asserted-by":"publisher","unstructured":"Langer-Gould A, Lucas R, Xiang AH, Chen LH, Wu J, Gonzalez E, Haraszti S, Smith JB, Quach H, Barcellos LF. MS sunshine study: sun exposure but not vitamin D is associated with multiple sclerosis risk in Blacks and Hispanics. Nutrients. 2018;10. https:\/\/doi.org\/10.3390\/nu10030268.","DOI":"10.3390\/nu10030268"},{"key":"1009_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1045731","volume":"13","author":"BCY Tse","year":"2022","unstructured":"Tse BCY, Ferguson AL, Koay YC, Grau GE, Don AS, Byrne SN. Exposure to solar ultraviolet radiation establishes a novel immune suppressive lipidome in skin-draining lymph nodes. Front Immunol. 2022;13:1045731. https:\/\/doi.org\/10.3389\/fimmu.2022.1045731.","journal-title":"Front Immunol"},{"key":"1009_CR109","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ana.27112","volume":"97","author":"F Alzamanan","year":"2024","unstructured":"Alzamanan F, Ding Y, Harroud A. Obesity and multiple sclerosis severity: a Mendelian randomization study. Ann Neurol. 2024;97:90\u20134. https:\/\/doi.org\/10.1002\/ana.27112.","journal-title":"Ann Neurol"},{"key":"1009_CR110","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1177\/1352458519877685","volume":"26","author":"AK Hedstrom","year":"2020","unstructured":"Hedstrom AK, Hossjer O, Hillert J, Stridh P, Kockum I, Olsson T, et al. The influence of human leukocyte antigen-DRB1*15:01 and its interaction with smoking in MS development is dependent on DQA1*01:01 status. Mult Scler. 2020;26:1638\u201346. https:\/\/doi.org\/10.1177\/1352458519877685.","journal-title":"Mult Scler"},{"key":"1009_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000973","volume":"18","author":"RE Mitchell","year":"2020","unstructured":"Mitchell RE, Bates K, Wootton RE, Harroud A, Richards JB, Davey Smith G, et al. Little evidence for an effect of smoking on multiple sclerosis risk: a Mendelian randomization study. PLoS Biol. 2020;18:e3000973. https:\/\/doi.org\/10.1371\/journal.pbio.3000973.","journal-title":"PLoS Biol"},{"key":"1009_CR112","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70058","volume":"32","author":"J Eva","year":"2025","unstructured":"Eva J, Olsson T, Alfredsson L, Hedstrom AK. Smoking and obesity interact to adversely affect disease progression and cognitive performance in multiple sclerosis. Eur J Neurol. 2025;32:e70058. https:\/\/doi.org\/10.1111\/ene.70058.","journal-title":"Eur J Neurol"},{"key":"1009_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612576","author":"A Xavier","year":"2023","unstructured":"Xavier A, Maltby VE, Ewing E, Campagna MP, Burnard SM, Tegner JN, et al. DNA methylation signatures of multiple sclerosis occur independently of known genetic risk and are primarily attributed to B cells and monocytes. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241612576.","journal-title":"Int J Mol Sci"},{"key":"1009_CR114","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213673","volume":"104","author":"C Goyne","year":"2025","unstructured":"Goyne C, Fair AE, Yilmaz D, Race J, Schuette A, Caillier SJ, et al. Epigenetic aging in pediatric-onset multiple sclerosis. Neurology. 2025;104:e213673. https:\/\/doi.org\/10.1212\/WNL.0000000000213673.","journal-title":"Neurology"},{"key":"1009_CR115","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ana.78043","volume":"99","author":"S Simpson-Yap","year":"2026","unstructured":"Simpson-Yap S, Morwitch E, Tanner SA, Thomson SM, Eisner A, Lea RA, et al. Epstein-Barr virus, lower vitamin D, low sun exposure, and HLA-DRB1*1501 risk variant share common epigenetic pathways leading to multiple sclerosis onset. Ann Neurol. 2026;99:341\u201355. https:\/\/doi.org\/10.1002\/ana.78043.","journal-title":"Ann Neurol"},{"key":"1009_CR116","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1212\/WNL.0000000000207489","volume":"101","author":"V Maltby","year":"2023","unstructured":"Maltby V, Xavier A, Ewing E, Campagna MP, Sampangi S, Scott RJ, et al. Evaluation of cell-specific epigenetic age acceleration in people with multiple sclerosis. Neurology. 2023;101:e679\u201389. https:\/\/doi.org\/10.1212\/WNL.0000000000207489.","journal-title":"Neurology"},{"key":"1009_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01397-2","volume":"14","author":"MP Campagna","year":"2022","unstructured":"Campagna MP, Xavier A, Lea RA, Stankovich J, Maltby VE, Butzkueven H, et al. Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity. Clin Epigenetics. 2022;14:194. https:\/\/doi.org\/10.1186\/s13148-022-01397-2.","journal-title":"Clin Epigenetics"},{"key":"1009_CR118","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/wnl.57.11.1976","volume":"57","author":"C Fusco","year":"2001","unstructured":"Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E, et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology. 2001;57:1976\u20139. https:\/\/doi.org\/10.1212\/wnl.57.11.1976.","journal-title":"Neurology"},{"key":"1009_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105873","volume":"118","author":"BC Zhang","year":"2025","unstructured":"Zhang BC, Schneider-Hohendorf T, Elyanow R, Pignolet B, Falk S, Wunsch C, et al. HLA-A *03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis. EBioMedicine. 2025;118:105873. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105873.","journal-title":"EBioMedicine"},{"key":"1009_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11139-3","volume":"10","author":"KE Carlstrom","year":"2019","unstructured":"Carlstrom KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, et al. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun. 2019;10:3081. https:\/\/doi.org\/10.1038\/s41467-019-11139-3.","journal-title":"Nat Commun"},{"key":"1009_CR121","doi-asserted-by":"publisher","unstructured":"Stampanoni Bassi M, Buttari F, Simonelli I, Gilio L, Furlan R, Finardi A, Marfia GA, Visconti A, Paolillo A, Storto M, et al. A single nucleotide ADA genetic variant is associated to central inflammation and clinical presentation in MS: implications for cladribine treatment. Genes (Basel), 2020;11. https:\/\/doi.org\/10.3390\/genes11101152.","DOI":"10.3390\/genes11101152"},{"key":"1009_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117750","author":"L Ferr\u00e8","year":"2021","unstructured":"Ferr\u00e8 L, Mascia E, Clarelli F, Roostaei T, Pignolet B, Brassat D, et al. Genetic factors implicated in the response to fingolimod treatment in multiple sclerosis patients: results from a pharmacogenetic meta-analysis. J Neurol Sci. 2021. https:\/\/doi.org\/10.1016\/j.jns.2021.117750.","journal-title":"J Neurol Sci"},{"key":"1009_CR123","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537.","journal-title":"JAMA Neurol"},{"key":"1009_CR124","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/jpm13010122","volume":"13","author":"L Ferre","year":"2023","unstructured":"Ferre L, Clarelli F, Pignolet B, Mascia E, Frasca M, Santoro S, Sorosina M, Bucciarelli F, Moiola L, Martinelli V, et al. Combining clinical and genetic data to predict response to fingolimod treatment in relapsing remitting multiple sclerosis patients: a precision medicine approach. J Pers Med. 2023;13:122. https:\/\/doi.org\/10.3390\/jpm13010122.","journal-title":"J Pers Med."},{"key":"1009_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087595","volume":"14","author":"NS Amin","year":"2023","unstructured":"Amin NS, Abd El-Aziz MK, Hamed M, Moustafa RR, El Tayebi HM. Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: a pharmacogenomics Egyptian study. Front Immunol. 2023;14:1087595. https:\/\/doi.org\/10.3389\/fimmu.2023.1087595.","journal-title":"Front Immunol"},{"key":"1009_CR126","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1007\/s00415-024-12608-6","volume":"271","author":"F Clarelli","year":"2024","unstructured":"Clarelli F, Corona A, Paakkonen K, Sorosina M, Zollo A, Piehl F, et al. Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study. J Neurol. 2024;271:7250\u201363. https:\/\/doi.org\/10.1007\/s00415-024-12608-6.","journal-title":"J Neurol"},{"key":"1009_CR127","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70227","volume":"32","author":"A Vilaseca","year":"2025","unstructured":"Vilaseca A, Urcelay E, Malhotra S, Castillo M, Aroca M, Vidal-Jordana A, et al. The variant rs7665090 is associated with interferon-beta response in multiple sclerosis patients. Eur J Neurol. 2025;32:e70227. https:\/\/doi.org\/10.1111\/ene.70227.","journal-title":"Eur J Neurol"},{"key":"1009_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106912","volume":"106","author":"RC Cardoso","year":"2026","unstructured":"Cardoso RC, de Matos MD, Duarte LA, Guimenes BD, Pavani GK, Gutman EG, et al. Influence of FCGR2A (rs1801274) and FCGR3A (rs396991) polymorphisms on natalizumab response on multiple sclerosis. Mult Scler Relat Disord. 2026;106:106912. https:\/\/doi.org\/10.1016\/j.msard.2025.106912.","journal-title":"Mult Scler Relat Disord"},{"key":"1009_CR129","doi-asserted-by":"publisher","DOI":"10.1177\/13524585261417130","author":"A Corona","year":"2026","unstructured":"Corona A, Clarelli F, Paakkonen K, Harroud A, Shchetynsky K, Zollo A, et al. Pharmacogenomics of response to interferon-beta and glatiramer acetate in multiple sclerosis: a multi-centric study. Mult Scler. 2026. https:\/\/doi.org\/10.1177\/13524585261417130.","journal-title":"Mult Scler"},{"key":"1009_CR130","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pneurobio.2016.02.001","volume":"152","author":"I Grossman","year":"2017","unstructured":"Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S, et al. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: insights from clinical research. Prog Neurobiol. 2017;152:114\u201330. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.02.001.","journal-title":"Prog Neurobiol"},{"key":"1009_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1016377","volume":"13","author":"E Hatchwell","year":"2022","unstructured":"Hatchwell E, Smith EB 3rd, Jalilzadeh S, Bruno CD, Taoufik Y, Hendel-Chavez H, et al. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies. Front Neurol. 2022;13:1016377. https:\/\/doi.org\/10.3389\/fneur.2022.1016377.","journal-title":"Front Neurol"},{"key":"1009_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1146027","volume":"14","author":"JR Berger","year":"2023","unstructured":"Berger JR, Hartung HP. Commentary: progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies. Front Neurol. 2023;14:1146027. https:\/\/doi.org\/10.3389\/fneur.2023.1146027.","journal-title":"Front Neurol"},{"key":"1009_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1629581","volume":"16","author":"PS Eis","year":"2025","unstructured":"Eis PS, Smith EB 3rd, Jalilzadeh S, Hatchwell E. Genetics of progressive multifocal leukoencephalopathy: update on case reports with an inborn error of immunity and risk variants found in drug-linked cases. Front Neurol. 2025;16:1629581. https:\/\/doi.org\/10.3389\/fneur.2025.1629581.","journal-title":"Front Neurol"},{"key":"1009_CR134","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214708","volume":"106","author":"BM Jacobs","year":"2026","unstructured":"Jacobs BM, Schalk L, Tregaskis-Daniels E, Scalfari A, Nandoskar A, Dunne A, et al. Genetic determinants of multiple sclerosis susceptibility in people from diverse ancestral backgrounds. Neurology. 2026;106:e214708. https:\/\/doi.org\/10.1212\/WNL.0000000000214708.","journal-title":"Neurology"},{"key":"1009_CR135","doi-asserted-by":"crossref","unstructured":"Carlstr\u00f6m KE, Agirre E, Sun T, Dumral \u00d6, Kabbe M, Mahmud N, Kit Lor Y, Pahlevan Kakhki M, Khademi M, Jagodic M, et al. Oligodendroglia as functional effectors of Multiple Sclerosis risk variants. 2025. bioRxiv. https:\/\/www.biorxiv.org\/content\/10.1101\/2025.11.11.687640v1.","DOI":"10.1101\/2025.11.11.687640"},{"key":"1009_CR136","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/acn3.51990","volume":"11","author":"BM Jacobs","year":"2024","unstructured":"Jacobs BM, Vickaryous N, Giovannoni G, Proitsi P, Waters S, Dobson R. Plasma proteomic profiles of UK Biobank participants with multiple sclerosis. Ann Clin Transl Neurol. 2024;11:698\u2013709. https:\/\/doi.org\/10.1002\/acn3.51990.","journal-title":"Ann Clin Transl Neurol"},{"key":"1009_CR137","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 2023;80:287\u201397. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5250.","journal-title":"JAMA Neurol"},{"key":"1009_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103839","volume":"63","author":"AJ Fortune","year":"2022","unstructured":"Fortune AJ, Fletcher JL, Blackburn NB, Young KM. Using MS induced pluripotent stem cells to investigate MS aetiology. Mult Scler Relat Disord. 2022;63:103839. https:\/\/doi.org\/10.1016\/j.msard.2022.103839.","journal-title":"Mult Scler Relat Disord"},{"key":"1009_CR139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade8560","volume":"16","author":"CC Gross","year":"2024","unstructured":"Gross CC, Schulte-Mecklenbeck A, Steinberg OV, Wirth T, Lauks S, Bittner S, et al. Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. Sci Transl Med. 2024;16:eade8560. https:\/\/doi.org\/10.1126\/scitranslmed.ade8560.","journal-title":"Sci Transl Med"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01009-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01009-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:53Z","timestamp":1790381033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01009-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":139,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01009-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jingni He, Nicholas B. Blackburn and Vilija G. Jokubaitis declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}